Supernus (SUPN) CFO Timothy Dec Exercises Performance Shares

What Happened
Timothy C. Dec, Senior Vice‑President & Chief Financial Officer of Supernus Pharmaceuticals (SUPN), converted/settled 1,250 performance-based derivative awards into common shares on August 12, 2026 (transaction code M). The conversion carried no cash exercise price (reported at $0.00). To satisfy tax withholding requirements (code F), the company withheld 604 of the issued shares at $46.57 per share, totaling $28,128.

Key Details

• Transaction date: August 12, 2026; Form 4 filed August 14, 2026 (appears timely).
• Conversion: 1,250 shares issued from derivatives (M) at $0.00.
• Tax withholding: 604 shares withheld (F) at $46.57/share = $28,128.
• Net shares delivered to Dec from the conversion: 1,250 issued − 604 withheld = 646 shares (per the filing).
• Footnotes: F1 notes the acquisition aggregate includes 251 shares acquired via the issuer’s Employee Stock Purchase Plan; F2 confirms the 604 shares were withheld to satisfy tax withholding for vesting of Performance Share Units; F3 explains the PSUs were awarded Feb 19, 2025 and vested after performance objectives were set May 3, 2025.
• Shares owned after the transaction: not specified in the excerpt of the filing provided.

Context

• M = exercise/conversion of a derivative (here, Performance Share Units converted into common stock). F = shares withheld to cover tax withholding.
• This was not a cash purchase or an open‑market sale by the insider; it reflects standard settlement/withholding when performance awards vest. Such withholding is routine and does not necessarily indicate a change in the insider’s view of the company.